Founded by Dr. Yann Chong Tan, Nuevocor is pioneering a new approach to treating genetic heart diseases like LMNA cardiomyopathy using advanced gene therapy. By targeting modifier genes and using precise delivery tools, they aim to fix disease mechanisms at the source. As a powerful start, Nuevocor is reshaping the future for patients everywhere.
The Beginning With Harsh Reality
Imagine being told that your heart is failing—not because of something you did, but because of a gene you were born with. Now imagine that your only real option for a cure is a heart transplant.
This is the harsh reality for people with genetic cardiomyopathies—a group of diseases that weaken the heart muscle, often at a young age. Among them, a condition called LMNA dilated cardiomyopathy is especially aggressive. By the age of 45, 7 in 10 people with this disease will either need a heart transplant, suffer a major cardiac event, or tragically pass away.
As a scientist, Tan had encountered this situation countless times, and this experience deeply affected him, leading him to come up with a solution to address the problem at its core—before the heart gives out.
This experience led to the emergence of Nuevocor, a biotech company based in Singapore and the USA, founded by Dr. Yann Chong Tan, a scientist and entrepreneur known for turning cutting-edge science into successful biotech ventures.
Read Also-Best Online Business Ideas for 2025 – Trending Ideas.
Nuevocor: Redefining Gene Therapy
At Nuevocor, Dr. Tan and his team had a simple but ambitious mission: to use gene therapy to treat genetic heart diseases. But they weren’t just trying to do what everyone else was doing.
“Most people think gene therapy is about replacing a bad gene with a good one,” Dr. Tan explained. “But in many heart diseases, even one faulty gene can cause serious problems, even if the other gene is perfectly fine. So adding a new gene doesn’t always fix it.”
Instead of simply adding a new gene, Nuevocor decided to take a different approach. They focused on finding “modifier genes”—genes that could help fix the damage caused by the faulty gene. Once they found these helpful genes, they used a tool called AAV (adeno-associated virus) to deliver them into heart cells, where they could start doing their job.
Their first big project focused on LMNA cardiomyopathy, a disease with no cure. The early results were astonishing. In animal tests, their therapy extended the lifespan more than four times. For a disease like this, that was a game changer.
To find these modifier genes, Nuevocor created their own platform, PrOSIA. It allowed them to study how genetic mutations affect the heart cells’ movement, stretching, and response to stress—things that made the disease so dangerous. By targeting these cellular changes, Nuevocor hoped to protect the heart at its most basic level. And with each breakthrough, they were one step closer to changing the future of heart disease treatment.
Read Also-Top Strategies for Business Growth – 10 Easy Steps.
Overcoming the Challenges of Gene Therapy
Turning an idea into reality is never easy, especially with the challenges of gene therapy. In recent years, high-dose treatments have raised safety concerns in clinical trials, and Nuevocor is taking these lessons to heart.
Given that, Dr. Tan is focused on making the therapy safer—using less virus and making sure the body doesn’t see the new proteins as a threat. It hasn’t been easy, but they’ve made real progress and believe they’re getting close.
Looking Ahead
Dr. Tan believed that nucleic acid-based medicines, like mRNA, antisense oligos, and gene vectors, were just beginning to make their mark. Once confined to research labs, they were now being used to treat real diseases.
The biggest challenge was delivering these treatments to the right cells safely and effectively, but he was hopeful. With new viral and non-viral delivery systems in development, he believed we were on the verge of targeting specific tissues with precision.
Read Also- Top 10 VC’s and Angel Investors in Singapore.
Turning Cutting-Edge Science into Life-Changing Solutions
Nuevocor is driven by the mission to offer hope to patients with few options left, using groundbreaking science to tackle diseases once thought untouchable.
The goal is clear: to bring these innovations to the clinic quickly, changing lives and turning the impossible into reality. For Dr. Tan, it’s a future worth working toward.
Dreaming big and working tirelessly to turn those dreams into reality isn’t easy. But Dr. Tan’s unwavering determination led him to build a multi-million dollar company from scratch. His journey is a true testament to passion, perseverance, and the power of belief.
Read Also- About Business Consultant: What Do They Do?
